Clinical Trials Logo

Bone Mass clinical trials

View clinical trials related to Bone Mass.

Filter by:
  • None
  • Page 1

NCT ID: NCT04524481 Recruiting - Osteoporosis Clinical Trials

Osteoporosis and Haemophilia

Start date: August 19, 2020
Phase:
Study type: Observational

The aim of this study is to evaluate the prevalence of osteoporosis in adult patients with haemophilia.

NCT ID: NCT01763775 Completed - Body Fat Disorder Clinical Trials

Clinical Trial of Transtek Body Fat Analyzer (GBF-1251-B & Other 3 Models)

BS-BT
Start date: October 2012
Phase: N/A
Study type: Interventional

The clinical protocol of the clinical testing of this device: 1. Objective of the test: To verify the functions and efficiency of devices. 2. Test methods and procedures: Comparison Test. 3. Device Under Test (DUT): Transtek Body Fat Analyzer, Model: GBF-1251-B, BF-1255-B, BF-1256-B, and GBF-1257-B. 4. Comparison device: Transtek, Glass Body Fat Analyzer, GBF-950-D. 5. Study endpoints: DUT and the comparison device are substantial equivalence. 6. Statistical methodology used: Description of statistical methods.

NCT ID: NCT01440894 Completed - Body Fat Disorder Clinical Trials

Clinical Trail of Transtek Glass Body Fat Analyzer

GBFA
Start date: February 2011
Phase: N/A
Study type: Observational

The clinical protocol of the clinical testing of this device: 1. Objective of the test: To verify the functions and efficiency of devices. 2. Test methods and procedures: Comparison Test. 3. DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D. 4. Comparison device: Transtek Glass Body Analyzer, GBF-950 (Predicate Device). 5. Study endpoints: Transtek devices and the predicate device are substantial equivalence. 6. Statistical methodology used: Description of statistical methods. 7. Result: Efficiencies of Transtek devices and predicate device are in the same level.

NCT ID: NCT01419782 Completed - Clinical trials for Effects of Vibration

Effects of Unilateral WBV on Muscleactivity of Contralateral Hip Adductor

WBV-BM
Start date: March 2011
Phase: N/A
Study type: Interventional

The aim of this study is to investigate effects of femur exposed to unilateral vibration on the rest muscle electrical activity of contralateral hip adductors and contralateral soleus H-reflex in young adult men. This study hypothesize that femur exposed to unilateral vibration may affect the rest muscle electrical activity of contralateral hip adductors. Vibration can effectively enhance muscle strength and power. Previous studies have shown that vibration increases muscle electromyographic (EMG) activity. It has been showed that bone has an effect on the increase in muscle EMG activity caused by vibration in healthy young adults in a study. In this study, it was reported that vibrations-induced increases in muscle electrical activity of flexor carpi radialis (FCR) was related to ultradistal radius bone mineral content (BMC) and the FCR H-reflex was suppressed or depressed during vibration. This findings were reported to support the assumption that the bone exposed to cyclic mechanical loading may neuronally regulate muscle activity.

NCT ID: NCT01310348 Completed - Clinical trials for Effects of Vibration

Effect of Bone on Vibration-Induced Muscle Strength Gain

EBVIMSG
Start date: April 2011
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether there is a relation between bone mineral density of lower limbs exposed to vibration and the muscle strength gain in the knee extensors and flexors, and a relation serum sclerostin level and the muscle strength gain in the knee extensors and flexors in healthy young adult women. Forty healthy young adult women are planned to include in this study. The participants meeting the criteria were randomized into two groups: the training group (20 cases) and the Control group (20 cases). The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Participants will be asked to stand upright on WBV platform. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration. The subjects will be asked to report negative side effects or adverse reactions in their training diary. In the Control group, sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period. Plasma sclerostin level and, the right and left knee flexor and extensor muscles strength will be measured before and after training period. Isokinetic torque will be measured with the Biodex (Biodex System 3 PRO Multijoint System Biodex Medical Inc. Shirley/NY USA)extremity-testing system. The right and left lower limbs bone mineral density (BMD) and muscle strength will be measured before training period. The BMD will be evaluated by bone densitometer (Norland XR-46 DXA, USA). Sclerostin levels will be measured by human sclerostin ELISA kit. The rest muscle electrical activity of right and left knee flexor and extensor muscles will be evaluated at pre-vibration, post- vibration and, during vibration. The rest muscle electrical activity will be measured by Powerlab (data acquisition system, ADInstruments, Australia) device.

NCT ID: NCT01296048 Completed - Body Fat Disorder Clinical Trials

Clinical Test for Transtek Glass Body Analyzer

GBA
Start date: November 2010
Phase: N/A
Study type: Observational

The clinical protocol of the clinical testing of this device: 1. Objective of the test: To verify the functions and efficiency of devices. 2. Test methods and procedures: Comparison Test. 3. DUT: Transtek Glass Body Analyzer, Model: GBF-830, GBF-835, GBF-950, and SA-15. 4. Comparison device: Scaleman Body Fat Scales, FS-148BW1 (Predicate Device). 5. Study endpoints: Transtek devices and the predicate device are substantial equivalence. 6. Statistical methodology used: Description of statistical methods. 7. Result: Efficiencies of Transtek devices and predicate device are in the same level.

NCT ID: NCT00724178 Completed - HIV Infection Clinical Trials

The Effect of Vitamin D and Calcium on Bone in Pediatric HIV

Start date: July 2003
Phase: Phase 2/Phase 3
Study type: Interventional

We have observed that vitamin D deficiency, as evidenced by low serum 25(OH)D concentrations, is common in children and adolescents with HIV infection. To determine whether vitamin D and calcium supplementation improve bone mineral content (BMC) and bone mineral density (BMD) in HIV-infected children and adolescents, we propose a double-blind, randomized, placebo-controlled trial comparing supplementation with oral vitamin D and calcium to placebo. The specific aims of this project are to: 1. Determine the effect of vitamin D and calcium supplementation on bone mineral accrual in HIV-infected children. We hypothesize that BMC and BMD will increase to a greater extent in HIV-infected children who receive supplementation with vitamin D and calcium. This hypothesis will be tested by comparing changes in BMC and BMD, measured by dual energy x-ray absorptiometry (DXA), after one and two years of treatment in HIV-infected children and adolescents receiving vitamin D and calcium supplementation compared to those receiving placebo. 2. Determine the effect of HIV infection and vitamin D and calcium supplementation on indices of mineral metabolism and markers of bone turnover. We hypothesize that indices of mineral metabolism and markers of bone formation and resorption will return toward normal in HIV-infected children and adolescents who are randomized to receive vitamin D and calcium supplementation. We will test these hypotheses by comparing longitudinal changes in indices of mineral metabolism and bone turnover markers in HIV-infected children and adolescents receiving vitamin D and calcium supplement versus those receiving placebo 3. Evaluate if vitamin D stores are a determinant of bone mass in HIV infected children and adolescents receiving HAART. We hypothesize that vitamin D stores, as assessed by serum 25-hydroxyvitamin D levels, are an important determinant of bone mass in HIV-infected children and adolescents receiving HAART. We will test this hypothesis by evaluating whether measurements of bone mass are associated with vitamin D stores, as measured by serum 25-hydroxyvitamin D levels and other indices of mineral metabolism, in treated HAART-treated HIV-infected children and adolescents.